Kiniksa Pharmaceuticals International (KNSA) Q2 2024 earnings summary

Executive summary

• ARCALYST Q2 2024 net product revenue reached $103.4 million, up 90% year-over-year, driven by increased patient demand and commercial execution.

• Full-year 2024 ARCALYST net product revenue guidance raised to $405–$415 million, reflecting accelerated growth.

• Abiprubart advanced into a fully funded Phase 2b trial for Sjögren’s Disease, with enrollment underway.

• Maintained a robust financial position with $218.8 million in cash, cash equivalents, and short-term investments as of June 30, 2024, and expect to remain cash flow positive on an annual basis.

• Completed redomiciliation from Bermuda to the United Kingdom in June 2024.

Financial highlights

• Total Q2 2024 revenue was $108.6 million, up from $71.5 million in Q2 2023, including $103.4 million from ARCALYST and $5.2 million in collaboration revenue.

• Net loss for Q2 2024 was $3.9 million, compared to net income of $15.0 million in Q2 2023, due to higher operating expenses and lower license revenue.

• Cash, cash equivalents, and short-term investments totaled $218.8 million as of June 30, 2024, with no debt.

• Collaboration expenses rose to $30.0 million in Q2 2024, primarily related to ARCALYST commercialization and profit sharing.

• Total operating expenses increased to $108.7 million in Q2 2024 from $74.6 million in Q2 2023.

Outlook and guidance

• 2024 ARCALYST net product revenue guidance increased to $405–$415 million, up from previous $370–$390 million, driven by strong year-to-date growth.

• Company expects to remain cash flow positive on an annual basis while investing in growth opportunities.

• Management expects existing cash and investments to fund operations and capital expenditures for at least the next 12 months.

• Ongoing focus on commercializing ARCALYST, advancing abiprubart clinical trials, and seeking partnerships for mavrilimumab.

• Anticipates continued operating losses as investments in R&D and commercialization persist.